logo of the EU drugs agency

You are viewing archived content

Please note that this page is a static copy of a previously published web page and is no longer actively maintained.
Be aware that the information contained here may be out-of-date.
For the most recent information, we recommend visiting the main website of the EMCDDA.

Figure INF-6. HCV antibody prevalence among injecting drug users - studies with national and subnational coverage

Part (iii) New injecting drug users (injecting less than 2 years), 2009 to 2010

 
 

Notes:

Black squares are samples with national coverage; blue triangles are samples with subnational (including local or regional) coverage. Differences between countries have to be interpreted with caution owing to different types of settings and/or study methods; national sampling strategies vary. Countries are presented by order of increasing prevalence, based on the average of national data or, if not available, of subnational data.

Source:

Reitox network.

Country Czech Republic Hungary Slovenia Finland Poland United Kingdom Austria Sweden Cyprus Slovakia Belgium Romania Greece Portugal Bulgaria
National 6.2 8.8 10.0 17.2     25.0   27.3       55.5 56.7  
National                         28.8 40  
Subnational 0.0     21.1 23.3 25.0 25.0   30.0 53.3 38.9 59.4   55.8
Subnational   18.2       19.9         8.3   29.4    
Subnational   33.3       23.7             45.8    
Subnational   12.2                     6.9    

inffig6c

 

Page last updated: Friday, 20 July 2012